ARMP Stock Summary and Trading Ideas (Armata Pharmaceuticals | AMEX:ARMP)

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Armata Pharmaceuticals trades on the AMEX stock market under the symbol ARMP.

As of January 28, 2025, ARMP stock price climbed to $2.08 with 907 million shares trading.

ARMP has a market cap of $75.20 million. This is considered a Micro Cap stock.

Last quarter Armata Pharmaceuticals reported $3 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.13.

In the last 3 years, ARMP traded as high as $5.79 and as low as $.83.

The top ETF exchange traded funds that ARMP belongs to (by Net Assets): VTI, VXF, IWC.

ARMP has underperformed the market in the last year with a price return of -49.1% while the SPY ETF gained +25.0%. ARMP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.0% and +3.0%, respectively, while the SPY returned +4.4% and +3.6%, respectively.

ARMP support price is $1.90 and resistance is $2.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARMP shares will trade within this expected range on the day.